170 related articles for article (PubMed ID: 18056174)
21. [The role of tumor marker CA 125 in the treatment of ovarian cancer].
Porsbjerg CM; Sørensen JB; Lund BA
Ugeskr Laeger; 1998 Feb; 160(7):995-1000. PubMed ID: 9477746
[TBL] [Abstract][Full Text] [Related]
22. HLA-G is a potential tumor marker in malignant ascites.
Singer G; Rebmann V; Chen YC; Liu HT; Ali SZ; Reinsberg J; McMaster MT; Pfeiffer K; Chan DW; Wardelmann E; Grosse-Wilde H; Cheng CC; Kurman RJ; Shih IeM
Clin Cancer Res; 2003 Oct; 9(12):4460-4. PubMed ID: 14555519
[TBL] [Abstract][Full Text] [Related]
23. Poor outcome of elderly patients with platinum-sensitive recurrent ovarian cancer: results from the SOCRATES retrospective study.
Pignata S; Ferrandina G; Scarfone G; Scollo P; Odicino F; Cormio G; Katsaros D; Frigerio L; Mereu L; Ghezzi F; Manzione L; Lauria R; Breda E; Alletti DG; Ballardini M; Vernaglia A; Sorio R; Tumolo S; Musso P; Magni G; Pisano C; Morabito A
Crit Rev Oncol Hematol; 2009 Sep; 71(3):233-41. PubMed ID: 19179095
[TBL] [Abstract][Full Text] [Related]
24. Osteopontin as an adjunct to CA125 in detecting recurrent ovarian cancer.
Schorge JO; Drake RD; Lee H; Skates SJ; Rajanbabu R; Miller DS; Kim JH; Cramer DW; Berkowitz RS; Mok SC
Clin Cancer Res; 2004 May; 10(10):3474-8. PubMed ID: 15161704
[TBL] [Abstract][Full Text] [Related]
25. Serum CA-125 level after 6 cycles of primary adjuvant chemotherapy is a useful prognostic factor for complete responders' survival in patients with advanced epithelial ovarian cancer.
Kim HS; Park NH; Chung HH; Kim JW; Song YS; Kang SB
Onkologie; 2008 Jun; 31(6):315-20. PubMed ID: 18547972
[TBL] [Abstract][Full Text] [Related]
26. Serum and tissue biomarkers as predictive and prognostic variables in epithelial ovarian cancer.
Gadducci A; Cosio S; Tana R; Genazzani AR
Crit Rev Oncol Hematol; 2009 Jan; 69(1):12-27. PubMed ID: 18595727
[TBL] [Abstract][Full Text] [Related]
27. Evaluation of apolipoprotein A1 and posttranslationally modified forms of transthyretin as biomarkers for ovarian cancer detection in an independent study population.
Moore LE; Fung ET; McGuire M; Rabkin CC; Molinaro A; Wang Z; Zhang F; Wang J; Yip C; Meng XY; Pfeiffer RM
Cancer Epidemiol Biomarkers Prev; 2006 Sep; 15(9):1641-6. PubMed ID: 16985025
[TBL] [Abstract][Full Text] [Related]
28. Klotho expression in epithelial ovarian cancer and its association with insulin-like growth factors and disease progression.
Lu L; Katsaros D; Wiley A; de la Longrais IA; Puopolo M; Yu H
Cancer Invest; 2008 Mar; 26(2):185-92. PubMed ID: 18259951
[TBL] [Abstract][Full Text] [Related]
29. The effect of maximal surgical cytoreduction on sensitivity to platinum-taxane chemotherapy and subsequent survival in patients with advanced ovarian cancer.
Eisenhauer EL; Abu-Rustum NR; Sonoda Y; Aghajanian C; Barakat RR; Chi DS
Gynecol Oncol; 2008 Feb; 108(2):276-81. PubMed ID: 18063020
[TBL] [Abstract][Full Text] [Related]
30. Subcellular localization of activated leukocyte cell adhesion molecule is a molecular predictor of survival in ovarian carcinoma patients.
Mezzanzanica D; Fabbi M; Bagnoli M; Staurengo S; Losa M; Balladore E; Alberti P; Lusa L; Ditto A; Ferrini S; Pierotti MA; Barbareschi M; Pilotti S; Canevari S
Clin Cancer Res; 2008 Mar; 14(6):1726-33. PubMed ID: 18347173
[TBL] [Abstract][Full Text] [Related]
31. [Identification of two potential serum biomarkers for ovarian cancer and clinical validation thereof].
Wang Q; Zhang W; Li DR; Li L
Zhonghua Yi Xue Za Zhi; 2008 Apr; 88(15):1012-6. PubMed ID: 18754431
[TBL] [Abstract][Full Text] [Related]
32. Serum cytokine profiling as a diagnostic and prognostic tool in ovarian cancer: a potential role for interleukin 7.
Lambeck AJ; Crijns AP; Leffers N; Sluiter WJ; ten Hoor KA; Braid M; van der Zee AG; Daemen T; Nijman HW; Kast WM
Clin Cancer Res; 2007 Apr; 13(8):2385-91. PubMed ID: 17438097
[TBL] [Abstract][Full Text] [Related]
33. Statistical interpretation of CA125 and Bcl-2 in serum of patients with late stage ovarian cancer.
Camlica H; Duranyildiz D; Tas F; Yasasever V
Am J Clin Oncol; 2008 Dec; 31(6):585-8. PubMed ID: 19060592
[TBL] [Abstract][Full Text] [Related]
34. Disease processes may be reflected by correlations among tissue kallikrein proteases but not with proteolytic factors uPA and PAI-1 in primary ovarian carcinoma.
Dorn J; Harbeck N; Kates R; Magdolen V; Grass L; Soosaipillai A; Schmalfeldt B; Diamandis EP; Schmitt M
Biol Chem; 2006 Aug; 387(8):1121-8. PubMed ID: 16895483
[TBL] [Abstract][Full Text] [Related]
35. Serological monitoring of epithelial ovarian cancer.
Fisken J; Leonard RC; Badley A; Jönrup I; Aspinall L; Sturgeon C; Roulston JE
Dis Markers; 1991; 9(3-4):175-90. PubMed ID: 1813209
[TBL] [Abstract][Full Text] [Related]
36. Quantification of free plasma DNA before and after chemotherapy in patients with advanced epithelial ovarian cancer.
Capizzi E; Gabusi E; Grigioni AD; De Iaco P; Rosati M; Zamagni C; Fiorentino M
Diagn Mol Pathol; 2008 Mar; 17(1):34-8. PubMed ID: 18303408
[TBL] [Abstract][Full Text] [Related]
37. Prognostic value of serum CA 125 bi-exponential decrease during first line paclitaxel/platinum chemotherapy: a French multicentric study.
Riedinger JM; Eche N; Basuyau JP; Dalifard I; Hacene K; Pichon MF
Gynecol Oncol; 2008 May; 109(2):194-8. PubMed ID: 18329083
[TBL] [Abstract][Full Text] [Related]
38. Discovery and application of protein biomarkers for ovarian cancer.
Gagnon A; Ye B
Curr Opin Obstet Gynecol; 2008 Feb; 20(1):9-13. PubMed ID: 18196999
[TBL] [Abstract][Full Text] [Related]
39. Circulating calprotectin in ovarian carcinomas and borderline tumors of the ovary.
Ødegaard E; Davidson B; Elgaaen BV; Fagerhol MK; Engh V; Onsrud M; Staff AC
Am J Obstet Gynecol; 2008 Apr; 198(4):418.e1-7. PubMed ID: 18241816
[TBL] [Abstract][Full Text] [Related]
40. The prognostic and predictive value of syntactic structure analysis in serous carcinoma of the ovary.
Palmer JE; Sant Cassia LJ; Irwin CJ; Morris AG; Janssen EA; Baak JP; Rollason TP
Int J Gynecol Pathol; 2008 Apr; 27(2):191-8. PubMed ID: 18317224
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]